6533b85afe1ef96bd12b942d

RESEARCH PRODUCT

Levetiracetam‐induced pediatric toxic epidermal necrolysis successfully treated with etanercept

Juan Ignacio MuñozAndrea EstébanezCarlos MonteagudoAlicia MonrabalM. D. RamonLuis Carlos Sáez-martínEsmeralda Silva

subject

musculoskeletal diseasesmedicine.medical_specialtybiologybusiness.industryDermatologymedicine.diseaseDermatologyToxic epidermal necrolysisInfliximabEtanercept030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisPediatrics Perinatology and Child Healthbiology.proteinmedicineTumor necrosis factor alphaLevetiracetamAntibodyskin and connective tissue diseasesbusinessmedicine.drug

description

Successful management of toxic epidermal necrolysis (TEN) with tumor necrosis factor-α inhibitors has been described in adults, but few cases have been reported in children. To date, only four pediatric cases of TEN treated with infliximab and one with etanercept have been published. We present the case of an 8-year-old boy diagnosed with TEN induced by levetiracetam, successfully treated with etanercept, systemic corticosteroids, and intravenous immunoglobulin.

yearjournalcountryeditionlanguage
2020-04-22Pediatric Dermatology
https://doi.org/10.1111/pde.14179